Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma
- PMID: 15101999
- DOI: 10.1111/j.1478-3231.2004.00886.x
Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma
Abstract
Background: Osteopontin (OPN) is known to be a secreted adhesive glycoprotein. Recent studies have reported that the overexpression of OPN is correlated with tumorigenesis, tumor aggressiveness, and poor prognosis in several types of human cancer. The aim of this study was to determine whether the expression of OPN in cases of intrahepatic cholangiocarcinoma (ICC) indicates the clinical outcome.
Methods: The expression of OPN protein was investigated immunohistochemically in surgically resected specimens from 73 patients, and the level of OPN mRNA was also examined by quantitative real-time reverse transcription-polymerase chain reaction (real-time RT-PCR) in nine samples of ICC. We examined the correlation between the expression of OPN and the clinicopathological factors, including overall survival, in patients with ICC.
Results: We detected the positive expression of OPN protein in 31 of 73 (42.5%) of the primary ICCs. Negative expression of OPN protein was significantly related to lymphatic permeation, perineural invasion, intrahepatic metastasis, and lymph node metastasis (P=0.0029, 0.0072, 0.0134, and 0.0101, respectively). Overall survival was significantly lower among the patients with a negative expression of OPN than it was among those with a positive expression of OPN. The negative expression of OPN protein and the lower levels of OPN mRNA were statistically significant (P=0.0139).
Conclusions: Decreased expression of OPN is considered to be a reliable indicator of tumor aggressiveness and clinical outcome in patients with ICC.
Similar articles
-
Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.Cancer Detect Prev. 2004;28(5):313-8. doi: 10.1016/j.cdp.2004.06.001. Cancer Detect Prev. 2004. PMID: 15542253
-
CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma.Cancer Lett. 2006 Apr 8;235(1):34-9. doi: 10.1016/j.canlet.2005.03.059. Epub 2005 Aug 25. Cancer Lett. 2006. PMID: 16125303
-
The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma.Am J Clin Oncol. 2006 Apr;29(2):138-42. doi: 10.1097/01.coc.0000204402.29830.08. Am J Clin Oncol. 2006. PMID: 16601431
-
Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.J Hepatobiliary Pancreat Surg. 2003;10(4):288-91. doi: 10.1007/s00534-002-0732-8. J Hepatobiliary Pancreat Surg. 2003. PMID: 14598147 Review.
-
[Prognosis factors of cholangiocarcinoma: contribution of recent molecular biology tools].Bull Cancer. 2009 Apr;96(4):405-15. doi: 10.1684/bdc.2008.0780. Bull Cancer. 2009. PMID: 19357015 Review. French.
Cited by
-
Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis.World J Gastroenterol. 2008 Apr 28;14(16):2501-10. doi: 10.3748/wjg.14.2501. World J Gastroenterol. 2008. PMID: 18442196 Free PMC article.
-
Osteopontin Expression in Patients with Hepatolith.Indian J Surg. 2015 Dec;77(Suppl 2):551-6. doi: 10.1007/s12262-013-0919-z. Epub 2013 May 18. Indian J Surg. 2015. PMID: 26730063 Free PMC article.
-
Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know.Cancers (Basel). 2022 Mar 15;14(6):1493. doi: 10.3390/cancers14061493. Cancers (Basel). 2022. PMID: 35326644 Free PMC article. Review.
-
Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.World J Gastroenterol. 2016 Mar 28;22(12):3441-50. doi: 10.3748/wjg.v22.i12.3441. World J Gastroenterol. 2016. PMID: 27022226 Free PMC article.
-
Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma.Hepatobiliary Surg Nutr. 2019 Dec;8(6):582-596. doi: 10.21037/hbsn.2019.03.14. Hepatobiliary Surg Nutr. 2019. PMID: 31929985 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous